{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"28"}]}],"title":"SVR, rs12979860 (CC), R; n=12, 50"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"58"}]}],"title":"SVR, rs12979860 (CC), NR; n=105, 205"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"18"}]}],"title":"SVR, rs12979860 (CT), R; n=12, 50"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"111"}]}],"title":"SVR, rs12979860 (CT), NR; n=105, 205"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"title":"SVR, rs12979860 (TT), R; n=12, 50"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"36"}]}],"title":"SVR, rs12979860 (TT), NR; n=105, 205"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"36"}]}],"title":"SVR, rs8099917 (TT), R; n=12, 50"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"89"}]}],"title":"SVR, rs8099917 (TT), NR; n=105, 205"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"}]}],"title":"SVR, rs8099917 (GT), R; n=12, 50"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"99"}]}],"title":"SVR, rs8099917 (GT), NR; n=105, 205"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"SVR, rs8099917 (GG), R; n=12, 50"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"17"}]}],"title":"SVR, rs8099917 (GG), NR; n=105, 205"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"21"}]}],"title":"RVR, rs12979860 (CC), R; n=11, 33"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"65"}]}],"title":"RVR, rs12979860 (CC), NR; n=106, 222"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"11"}]}],"title":"RVR, rs12979860 (CT), R; n=11, 33"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"118"}]}],"title":"RVR, rs12979860 (CT), NR; n=106, 222"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"RVR, rs12979860 (TT), R; n=11, 33"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"39"}]}],"title":"RVR, rs12979860 (TT), NR; n=106, 222"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"28"}]}],"title":"RVR, rs8099917 (TT), R, n=11, 33"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"97"}]}],"title":"RVR, rs8099917 (TT), NR; n=106, 222"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]}],"title":"RVR, rs8099917 (GT), R; n=11, 33"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"107"}]}],"title":"RVR, rs8099917 (GT), NR; n=106, 222"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"RVR, rs8099917 (GG), R; n=11, 33"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"18"}]}],"title":"RVR, rs8099917 (GG), R; n=106, 222"}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"205"}],"units":"Participants"}],"description":"There are two genetic variants (rs12979860 and rs8099917) mapping near IL28B associated with both interferon-induced SVR and spontaneous HCV clearance. IL28B genotype distribution by response to antiviral therapy (SVR/RVR responders: those who achieved SVR/RVR; SVR/RVR non-responders: those who did not achieve SVR/RVR) was assessed. The effect of genotype was tested by comparing participants that carried 2 copies of the IL28B favorable response allele versus the others (recessive model). Genotypes at rs12979860 were coded as: CC=1, CT or TT=0; rs8099917 was coded as TT=1, GT or GG=0.","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=100 Gi/L) in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"NUMBER","populationDescription":"Pharmacogenetic (PGx) Sub-Population: participants enrolled in this study who provided written informed consent for PGx research with a blood sample for genotyping and who were successfully genotyped for at least one of the two genetic markers under study. Only those participants who were analyzed for SVR and RVR were considered.","reportingStatus":"POSTED","timeFrame":"From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)","title":"Number of Participants Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3)","type":"SECONDARY","unitOfMeasure":"participants"}